Paris-based Diabeloop evaluated DBLG1 in a large, multi-country patient cohort. Results demonstrated constant improvement in time in range and time in hypoglycemia remaining significantly low.
The company said in a news release that the results, combined with trust in its algorithm, led to fewer interactions with the device and improved quality of life. Diabeloop presented data at the European Association for the Study of Diabetes (EASD) Annual Meeting 2022.
Diabeloop’s cohort includes 4,162 patients across Germany, Italy, Spain, The Netherlands and Switzerland. The study demonstrated time-in-range improvements of 17.6% over one year of real-world use. Patients spent less than 20 minutes per day in hypoglycemia (low blood sugar). Diabeloop said the maximum time in hypoglycemia accepted internationally totals 60 minutes per day.
The company said its algorithm performance proved to garner patient trust with meal management capabilities. Users can access meal size pre-configurations and declare their meals on the food logging function. They can personalize carb intake and receive recommended insulin doses based on trends from their food declarations.
Diabeloop said it is working on new versions to allow for optimal management without declarations. Testimonials demonstrated trust in DBLG1’s performance to skip meal declarations or approximate quantities and still achieve satisfying results.
The company called feedback through the first year of commercialization “tremendous.” Highlights include time-saving capabilities, mental load alleviation and quality of life improvements.
“There is nothing more fueling for us than seeing DBLG1 perform over many months while it contributes to people with diabetes various lifestyles and needs,” Diabeloop co-founder and CEO Erik Huneker said. “We have now equipped 10,000 patients and look forward to providing more personalization, ever more simplicity of use and more choices…to more and more people with diabetes.”
